Article Details
Retrieved on: 2024-04-07 05:49:42
Tags for this article:
Click the tags to see associated articles and topics
Summary
Biocytogen and TRACON Pharmaceuticals announce FDA approval for a Phase 1/2 clinical study of a novel biopharma therapy, YH001, targeting CTLA-4 in combination with envafolimab and doxorubicin for treating sarcoma. The study focuses on rare and common sarcoma subtypes, highlighting advancements in cancer immunotherapy and biotechnology.
Article found on: www.theglobeandmail.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here